Aethlon Medical Amends Agreements, Allowing Immediate Exercisability of Pre-Funded Warrants
AEMD sits 36% above its 52-week low of $2.22.
Summary
Aethlon Medical amended its financing agreements, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable and accelerating potential dilution.
Key Events · Financing and Capital Events · AEMD
-
Amendment to Securities Purchase Agreement
On January 22, 2026, Aethlon Medical and an institutional investor amended their Securities Purchase Agreement from December 5, 2025.
-
Amendment to Pre-Funded Common Stock Purchase Warrant
Concurrently, the company and the investor also amended the Pre-Funded Common Stock Purchase Warrant from December 8, 2025.
-
Removal of Shareholder Approval Requirement
Both amendments removed the condition requiring shareholder approval under Nasdaq 5635 for the pre-funded warrants to become exercisable.
-
Immediate Exercisability of Warrants
As a direct result of these amendments, the pre-funded warrants are now immediately exercisable, accelerating potential dilution for existing shareholders.
Analysis · AEMD · Industrial Applications And Services
Aethlon Medical has amended its Securities Purchase Agreement and Pre-Funded Common Stock Purchase Warrant, removing the requirement for shareholder approval (under Nasdaq 5635) for the pre-funded warrants to become exercisable. This change, effective January 22, 2026, means these warrants are now immediately exercisable, accelerating potential dilution. This follows recent filings, including a DEF 14A on January 16, 2026, which sought shareholder approval for proposals enabling over 200% dilution, and an S-1 registration on January 7, 2026, for the resale of over 2 million shares underlying various warrants. The removal of this shareholder safeguard for pre-funded warrants is a significant negative development, as it allows for immediate dilution without prior shareholder consent, intensifying the dilution risk for existing investors.
At the time of this filing, AEMD was trading at $3.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $2.22 to $64.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.